Leerink notes Pfizer (PFE) announced that Chris Boshoff will become the new Chief Scientific Officer, succeeding Mikael Dolsten. The firm views Boshoff as a strong choice for CSO given his impressive background, experience, and judgment. As CSO, Boshoff will be responsible for both oncology and non-oncology R&D. Roger Dansey will become the interim Chief Oncology Officer, and Johanna Bendell will join Pfizer as Oncology Chief Development Officer, filling Dansey’s previous role. Leerink sees it as marginally disappointing that Dansey will depart Pfizer given his exceptional track record as CMO and interim CEO of Seagen, but not particularly surprising. The firm keeps a Market Perform on the shares.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- U.K.’s CAT fines Pfizer, Flynn GBP 69M for excessive pricing after CMA probe
- Pfizer (PFE) Appoints Company Insider Chris Boshoff as New Head of R&D
- Pfizer confirms Chris Boshoff as chief scientific officer
- Pfizer selects Chris Boshoff as chief scientific officer, WSJ reports
- Pfizer announces EC approval for Hympavzi